Clinical Trial

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated July 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
Acute liver failure (ALF) is a serious condition in which the liver suddenly stops working, often leading to life-threatening complications. While N-Acetylcysteine (NAC) is widely used to treat ALF caused by acetaminophen overdose, its benefits in ALF due to other causes, such as viral infections or drug reactions, remain uncertain. This study is a randomized controlled trial designed to investigate whether NAC can improve survival rates and reduce hospital stays in patients with non-acetaminophen-induced ALF. Participants will be randomly assigned to receive either NAC along with standard supportive care or standard supportive care alone. The study will measure survival rates, hospital stay duration, and improvement in liver function tests. By exploring NAC's potential benefits beyond acetaminophen-related cases, this research aims to provide evidence-based guidance on how to better manage patients with ALF from other causes.
Trial Details
NCT Number NCT06872372
Lead Sponsor Lahore General Hospital
Conditions Acute Liver Failure, Drug-Induced Liver Injury
Enrollment 62 participants
Start Date 2025-01-15
Primary Completion 2025-07-15 (estimated)
Study Completion 2025-07-15 (estimated)
Updated on ClinicalTrials.gov 2025-03-12